AUA

An aggressive treatment, such as bladder removal, may be necessary in patients with early stage micropapillary bladder cancer because the disease may behave more like late-stage conventional urothelial carcinoma.

"This particular study comes from our human randomized trial that we hope will be the final step before FDA approval for the technology,” says Mathew D. Sorensen, MD, MS, FACS.

In this interview, Kevin Zorn, MD, discusses 3-year results from a study of robot-assisted Aquablation procedures in treating men with large prostates.

“We have the rising spectra of national and international antibiotic resistance, which is becoming a huge international medical issue,” says J. Curtis Nickel, MD.

"The challenges involved in medical stone prevention are first, making the diagnosis with current protocols," says Glenn M. Preminger, MD.

“BCG-unresponsive non–muscle-invasive bladder cancer is really [an] evolving space with a lot of uncertainty,” says Kelly L. Stratton, MD.

“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.

"The take-home message is that Optilume is safe, and that it's superior to standard DVIU or dilation for the treatment of recurrent anterior urethral strictures that are less than 3 cm in length," says Sean P. Elliott, MD, MS, FACS.

The MV140 vaccine "will be a game changer for women's health in the future," says J. Curtis Nickel, MD.

“The notable finding was that the combination was well tolerated,” says Kelly L. Stratton, MD.

“Although numbers of participants with certain disease risk features were small, the DFS benefit was consistent across subgroups,” said lead study author Toni K. Choueiri, MD.

Phase 1/2 data showed that large surface area microparticle docetaxel is safe with early signs of clinical activity in patients with high-risk non–muscle invasive bladder cancer.

The minimally invasive single port robot-assisted radical prostatectomy led to high postoperative continence rates and significant improvements in IPSS and PVR measures.

The mitomycin-containing reverse thermal gel UGN-101 (Jelmyto) produced durable responses in patients with low-grade upper tract urothelial carcinoma.

The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.

“At 365 days, the rate of return procedures was lowest for the UroLift. The rate of return procedures was higher after Rezum versus UroLift,” says Steven A. Kaplan, MD.

“We need to treat our patients with stones, both medically and surgically,” says Glenn M. Preminger, MD.

Data from the phase 1b ABC Trial showed that adding avelumab to BCG induction therapy may be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

“Asian men had the lowest rates of ED treatments compared to Caucasian men, regardless of modality of treatment,” says Tony Chen, MD.

"The device is noninvasive and used in awake subjects. This case demonstrates that even chronic fragments can be successfully cleared, sometimes within hours of the procedure, even if they have not previously cleared for months,” said Mathew Sorensen, MD.

“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.

Interim results from the ROBUST III trial were presented at the 2021 AUA Annual Meeting.

Long-term findings from 2 cohorts of a phase 3 study showed sustained efficacy with the novel intravesical gene therapy in patients with BCG-unresponsive non–muscle invasive bladder cancer.

“The combination of Vicineum and durvalumab in BCG-unresponsive NMIBC is tolerated well and no new safety signals were identified; the doublet has a similar safety profile to [what is seen with] both agents used individually,” says Sandeep Gurram, MD.

“The combination of TAR-200 and cetrelimab is being studied to determine whether it can improve patient outcomes,” says study coauthor Stephen B. Williams, MD, MS.

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec.

“From [the results] of this study, we propose the timing and indication of cytoreductive nephrectomy,” said Hiroshi Kikuchi, MD, PhD.

Adding N-803 to Bacille Calmette-Guérin achieved a complete response in nearly three-fourths of patients with BCG-unresponsive, non-muscle invasive bladder cancer.

“Level 1 data on shock wave therapy for ED is still pending. It should not be marketed as having such,” says James Weinberger, MD, MBA.

“We recommend doing the spot cautery,” says Andrew Higgins, MD.